Navigation Links
Sofinnova Raises $500 Million Biotech Venture Fund
Date:7/23/2014

MENLO PARK, Calif., July 23, 2014 /PRNewswire/ -- Sofinnova Ventures, a Menlo Park based investment firm, today announced the closing of Sofinnova Venture Partners IX, L.P. at the hard cap of $500 million and in excess of the initial fund target of $425 million.

Sofinnova focuses exclusively on helping entrepreneurs build successful biotechnology companies. Consistent with recent funds, SVP IX will provide capital primarily to companies with promising later stage clinical programs, along with select investments in earlier stage opportunities. Investments will focus on developing specialty pharmaceuticals and orphan disease products. Sofinnova intends to continue the firm's successful strategy of sourcing investments in both the United States and Europe.

"We value the support that our returning limited partners and new investors have shown for our strategy and the Sofinnova team," commented Jim Healy, General Partner, Sofinnova. "Sofinnova is proud to partner with talented entrepreneurs who are focused on developing innovative medicines that can positively impact patient care. We remain committed to working with our collective network to identify and develop important new drugs, build successful companies, and continue to generate significant returns for our investors."

Sofinnova recent IPOs and exits include Labrys (acquired by Teva), ZS Pharma (IPO, ZSPH), Versartis (IPO, VSAR), Aerie (IPO, AERI), Tesaro (stock sale, TSRO), SARcode (acquired by Shire), NextWave (acquired by Pfizer), Intellikine (acquired by Takeda), Hyperion (IPO, HPTX), Durata (IPO, DRTX), Amarin (stock sale, AMRN),  Vicept (acquired by Allergan) and Preglem (acquired by Gedeon Richter).

The partners of SVP IX are Srini Akkaraju, MD, PhD, Jim Healy, MD, PhD, Anand Mehra, MD, Mike Powell, PhD, Lars Ekman, MD, PhD, David Kabakoff, PhD and Jay Shepard.

About Sofinnova Ventures

Sofinnova Ventures has over 40 years of experience building life science companies into market leaders. With $1.8 billion in committed capital, the firm applies capital and expertise to take companies from inception to exit. Sofinnova's investment team of MDs, PhDs and seasoned executives has significant scientific, operational and strategic experience, and specializes in financing clinical therapeutics. Our team partners with entrepreneurs to build successful companies, advance medicine and address patients' unmet medical needs.

Sofinnova is headquartered in Menlo Park, CA with offices in La Jolla, CA and Dublin, Ireland. www.sofinnova.com.

Contact Information:
Jennifer James
Partner – Investor Relations and Marketing
Sofinnova Ventures
(650) 681-8429; Jennifer@sofinnova.com

Logo - http://photos.prnewswire.com/prnh/20130724/SF52046LOGO-b


'/>"/>
SOURCE Sofinnova Ventures
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Edico Genome Raises $10 Million in Series A Financing to Commercialize DRAGEN Chip to Overcome Sequencing Data Analysis Bottleneck
2. Tute Genomics Raises $1.5M for Cloud-based Genome Analytics & Machine-learning for Gene Discovery
3. Curoverse Raises $1.5 Million to Build Open Source Platform for Genomic and Biomedical Big Data
4. The Holistic Sanctuary Raises Alarm About Teenage Drug Addiction
5. Immune Design Raises Up to $49 Million Series C Financing
6. Acacia Pharma Raises £15 Million ($23.5 Million) to Advance Clinical Development of Lead Products for Supportive Care
7. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
8. Advanced Animal Diagnostics Raises $6 Million for On-farm Diagnostics
9. OriGene Technologies Raises $21.3 Million in Series C Funding
10. Z Trim Holdings Announces Conclusion of Successful Warrant Exercise Program: Raises $2.195 Million
11. Strand Raises Series B From Burrill & Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Denmark , March 22, 2017  Ascendis ... utilizes its innovative TransCon technology to address significant ... financial results for the full year ended December ... significant year for our company as we broadened ... a leading, integrated rare disease company with an ...
(Date:3/22/2017)... --  iSpecimen ®, the marketplace for human ... (DPS), a full-service anatomic pathology reference lab serving ... , has joined a program offered by iSpecimen ... to make human biospecimens and associated data available to ... in 2015 as a collaboration between iSpecimen and DHIN, ...
(Date:3/22/2017)... 2017   Boston Biomedical , an industry leader ... target cancer stemness pathways, today announced its Board of ... Chief Executive Officer, effective April 24, 2017. ... , M.D., FACP, who has led Boston Biomedical since ... leadership, Boston Biomedical has grown from a "garage startup" ...
(Date:3/22/2017)... , ... March 21, 2017 , ... ... biologics. To acquire information on the desired increase and/or decrease in antibody-dependent cellular ... for rapid N-glycosylation profiling of therapeutic antibodies. , To meet this demand, ...
Breaking Biology Technology:
(Date:2/28/2017)... , February 28, 2017 News solutions for ... ... from 14 to 16 March, Materna will present ... show how seamless travel is a real benefit for passengers. ... biometrics to their passenger touch point solutions to take passengers through ...
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... Recidivism and Reentry. "Too often, too ... prisons and county jails are trying to tackle ... inmates and friends and family members. While significant steps ...
(Date:2/21/2017)... and PORTLAND, Ore. , ... and the Avamere Family of Companies (Avamere Health Services, ... announced a six-month research study that will apply the ... eldercare at senior living and health centers. By analyzing ... hopes to gain insights into physical and environmental conditions, ...
Breaking Biology News(10 mins):